



Contact: Ralph Barry, Chief Business Officer
Aegis Therapeutics LLC
1-858-618-1400 Ext. 102
Email: rbarry@aegisthera.com

Aegis Therapeutics To Introduce Its Cedar Therapeutics Inc. Spin-out Company at the Frost and Sullivan Venture Connections 2007 Symposium in San Francisco

SAN DIEGO, CA March 1, 2007/MarketWire/-- Aegis Therapeutics, a drug delivery technology licensing company and leader in transmucosal drug delivery, will introduce its recently formed Cedar Therapeutics Inc. spin-out company at the Frost and Sullivan Venture Connections 2007 Executive Symposium on March 14, 2007. Cedar Therapeutics was formed to develop novel, proprietary, and superior formulations for certain drugs recently or soon-to-be off-patent addressing a current total market in excess of \$11 Billion and eligible for FDA 505(b)2 accelerated regulatory treatment using Aegis' proprietary Intravail® and ProTek® advanced proprietary drug delivery and formulation technologies.

Aegis Executive Chairman, Donald W. Grimm, stated: "The formation of Cedar provides another means of maximizing the utility of our underlying Aegis technologies that is non-competitive with, but rather directly supportive of, our current licensees. It is also consistent with our highly successful Aegis business charter, which is to provide licenses, on a product-by-product exclusive basis, for the broadest possible range of clinical applications. We are encouraged by very early venture capital interest in establishing this spin-out and look forward to working with new partners to create important new clinical options for physicians and patients alike."

The Intravail® and ProTek® technologies enable the non-invasive delivery of a broad range of protein, peptide and non-peptide macromolecular and small molecule therapeutics with exceptionally high and unmatched bioavailability, comparable in efficiency to subcutaneous injection, via the intranasal administration route. Additional Intravail® competitive advantages include rapid drug absorption and onset of action, controlled transient permeation of the nasal mucosal barrier with no or minimal irritation, avoidance of gastric hydrolysis in the stomach and "first pass effect" elimination by the liver that can accompany oral administration, greater patient convenience and compliance, elimination of needlestick injuries and associated transmission of bloodborne pathogens, compatibility with a broad range of widely available off-the-shelf metered nasal spray delivery devices, ease of formulation, and compatibility with routine homogeneous formulation and dispensing manufacturing processes for ease of scale-up and production.

Information about the conference may be obtained from the following website:
<http://www.frost.com/prod/servlet/cpo/94924239>

About Aegis Therapeutics

Aegis Therapeutics LLC is a drug delivery technology company commercializing its patented or proprietary drug delivery and drug formulation technologies through product-specific licenses. Our Intravail® drug delivery technology enables the non-invasive delivery of a broad range of protein, peptide and non-peptide macromolecular therapeutics that can currently only be administered by injection. Aegis' Intravail® absorption enhancement agents provide exceptionally high and unmatched bioavailability performance, comparable in efficiency to subcutaneous injection, via the intranasal administration route. Intravail® has also been successfully applied to buccal, oral, and rectal administration of both small molecule and peptidic drugs. Our ProTek® technology allows creation of proprietary, easily manufacturable, and stable aqueous or lyophilized dosage forms that maintain the integrity and physiological activity of many protein and peptide therapeutics. ProTek® technology is applicable to injectable, intranasal, and other dosage forms of peptide or protein therapeutics.

For more information about Aegis, please visit the Aegis website at: <http://www.aegisthera.com>.

###